S-1 Versus Capecitabine in the First Line Treatment of MCC Patients. (SALTO)
S1 Versus Capecitabine in the First Line Treatment of Metastatic Colorectal Cancer Patients, the SALTO Randomised Phase III Study of the Dutch Colorectal Cancer Group. A Safety Evaluation of Oral Fluoropyrimidines
Sponsor: Dutch Colorectal Cancer Group
A PHASE3 clinical study on Colorectal Cancer and Metastases, this trial is completed. The trial is conducted by Dutch Colorectal Cancer Group and has accumulated 7 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Mar 2018 — Jun 2018 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
▶ Show 2 earlier versions
-
Feb 2017 — Mar 2018 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Dec 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Dutch Colorectal Cancer Group
- Nordic Pharma SAS
For direct contact, visit the study record on ClinicalTrials.gov .